发明名称 Induction of mucosal tolerance to antigens
摘要 The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of Foxp3+ and/or IL-10 and/or TGF-β producing regulatory T-cells, capable of suppressing undesired immune responses toward an antigen, by oral delivery of said antigen in combination with an immunosuppressing cytokine secreting micro-organism.
申请公布号 US9539291(B2) 申请公布日期 2017.01.10
申请号 US201414216887 申请日期 2014.03.17
申请人 INTREXON ACTOBIOTICS NV 发明人 Rottiers Pieter;Snoeck Veerle
分类号 A61K35/74;A61K35/747;A61K38/20;A61K39/00;A61K39/39;A61K39/35;A61K39/395;A61K36/064 主分类号 A61K35/74
代理机构 Drinker Biddle & Reath LLP 代理人 Drinker Biddle & Reath LLP
主权项 1. A medicament, nutraceutical, or medical food for treating and/or alleviating type I diabetes or for inducing immune tolerance to type I diabetes comprising a beta cell autoantigen in type I diabetes and an IL-10 secreting Lactococcus lactic.
地址 Zwijnaarde BE